Cited by 1,547Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.

High-Density Lipoprotein — The Clinical Implications of Recent Studies

Desforges, Jane F., Gordon, David J., Rifkind, Basil M.·1989·New England Journal of Medicine

DOI 10.1056/nejm198911093211907

Open this paper in CoChat — free account

Abstract

DESPITE early observations suggesting an inverse relation between serum levels of high-density lipoprotein (HDL) cholesterol and coronary disease,1 2 3 the possible protective role of HDL in atherogenesis received little attention until its "rediscovery" by Miller and Miller4 in 1975 and the publication of confirmatory results from the Honolulu,5 Framingham,6 and Tromsø7 heart studies in 1976 and 1977. In the ensuing decade, research into the biochemistry, metabolism, epidemiology, and genetics of HDL has expanded rapidly, but many questions remain unanswered. The recent publication of the results of the Helsinki Heart Study8 , 9 — in which simultaneous 11 percent increases in HDL and reductions . . .

Integrity signals

Registry

Crossref · 10.1056/nejm198911093211907

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Self-citation
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.256.20.2835 · Cited by 2,512
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,458
The plasma lecithin:cholesterol acyltransferase reaction
Glomset, J. A. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43114-1 · Cited by 2,396
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts
Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654
Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man.
Mattson, F. H., & Grundy, S. M. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34389-3 · Cited by 1,354

Show all 50 references

Research works printed but not linked: 10

Gofman, 1954, Plasma, 2, 413
Hulley, 1977, JAMA, 238, 2269, 10.1001/jama.1977.03280220037017 · DOI
Ernst, 1980, Circulation, 62, IV-41
Sacks, 1985, JAMA, 254, 1337, 10.1001/jama.1985.03360100087019 · DOI
Davis, 1980, Circulation, 62, IV-24
Enger, 1979, Artery, 5, 170
Levy, 1987, Circulation, 76, IV-167
Superko, 1986, JAMA, 256, 2714, 10.1001/jama.1986.03380190084030 · DOI
Hunninghake D, Gordon DJ, Tamir I, Rifkind BM. Management of hyperlipidemia. In: Pradhan SN, Maickel RP, Dutta SN, eds. Textbook of pharmacology. Bethesda, Md.: SP Press International, 1986:617–33.
Castelli, 1986, JAMA, 256, 2835, 10.1001/jama.1986.03380200073024 · DOI

Sorted by citations

Items 401–500 of 1,000

Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity
Huuskonen, J., Ekström, M., Tahvanainen, E., Vainio, A., Metso, J., Pussinen, P. J., Ehnholm, C., Olkkonen, V. M., & Jauhiainen, M. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00429-3 · Cited by 66
“stimulated research into this lipoprotein fraction [1].”
Quantitative Trait Loci Analysis for Plasma HDL-Cholesterol Concentrations and Atherosclerosis Susceptibility Between Inbred Mouse Strains C57BL/6J and 129S1/SvImJ
Ishimori, N., Li, R., Kelmenson, P. M., Korstanje, R., Walsh, K. A., Churchill, G. A., Forsman‐Semb, K., & Paigen, B. J. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000104027.52895.d7 · Cited by 66
“Advantages of this phenotype-driven method are (1) detection of rate-limiting genetic defects, (2) discrimination of rate-limiting defects from secondary (downstream) effects, and (3) identification of novel genes or of known genes with novel functions.”
Method
A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma
Pérusse, M., Pascot, A., Després, J., Couillard, C., & Lamarche, B. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31585-6 · Cited by 66
Acetylated low density lipoprotein reduces its ligand activity for the scavenger receptor after interaction with reconstituted high density lipoprotein.
Miyazaki, A., Sakai, M., Suginohara, Y., Hakamata, H., Sakamoto, Y., Morikawa, W., & Horiuchi, S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37683-4 · Cited by 66
Very low high-density lipoproteins without coronary atherosclerosis
Rader, D. J., Ikewaki, K., Duverger, N., Feuerstein, I. M., Brewer, H. B., & CONNOR, W. E. (1993) · The Lancet · doi:10.1016/0140-6736(93)92933-k · Cited by 66
Determining Gender by Raman Spectroscopy of a Bloodstain
Sikirzhytskaya, A., Sikirzhytski, V., & Lednev, I. K. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02986 · Cited by 66
High-Density Lipoprotein Attenuates Th1 and Th17 Autoimmune Responses by Modulating Dendritic Cell Maturation and Function
Tiniakou, I., Drakos, E., Sinatkas, V., Eck, M. V., Zannis, V. I., Boumpas, D. T., Verginis, P., & Kardassis, D. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402870 · Cited by 68
“Although it has been best recognized for its inverse correlation with cardiovascular events (2, 3), accumulating evidence has”
Background
NFκB Regulates Plasma Apolipoprotein A-I and High Density Lipoprotein Cholesterol through Inhibition of Peroxisome Proliferator-activated Receptor α
Morishima, A., Ohkubo, N., Maeda, N., Miki, T., & Mitsuda, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306336200 · Cited by 65
Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies
Craeyveld, E. V., Gordts, S. C., Nefyodova, E., Jacobs, F., & Geest, B. D. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0722-x · Cited by 65
“Plasma levels of high-density lipoprotein (HDL) cholesterol and its major apolipoprotein (apo), apo A-I, are inversely correlated with the risk of ischemic cardiovascular diseases [6].”
Background
Increased Fecal Bile Acid Excretion in Transgenic Mice With Elevated Expression of Human Phospholipid Transfer Protein
Post, S. M., de Crom, R., van Haperen, R., van Tol, A., & Princen, H. M. G. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000067702.22390.20 · Cited by 65
Association between single-nucleotide polymorphisms in the endothelial lipase (LIPG) gene and high-density lipoprotein cholesterol levels
Mank-Seymour, A. R., Durham, K. L., Thompson, J. F., Seymour, A. B., & Milos, P. M. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2003.12.001 · Cited by 65
Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data
Fredenrich, A., & Bayer, P. M. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70029-0 · Cited by 65
Serum testosterone level is the major determinant of the male-female differences in serum levels of high-density lipoprotein (HDL) cholesterol and HDL2 cholesterol
Asscheman, H., Gooren, L. J., Megens, J. A. J., Nauta, J. J. P., Kloosterboer, H. J., & Eikelboom, F. A. (1994) · Metabolism · doi:10.1016/0026-0495(94)90170-8 · Cited by 65
TATA box polymorphisms in human gene promoters and associated hereditary pathologies
Savinkova, L. K., Ponomarenko, M. P., Ponomarenko, P. M., Drachkova, I. A., Lysova, M. V., Arshinova, T., & Kolchanov, N. A. (2009) · Biochemistry (Moscow) · doi:10.1134/s0006297909020011 · Cited by 64
Spondyloarthropathies: An independent cardiovascular risk factor?
Mathieu, S., Motreff, P., & Soubrier, M. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.05.001 · Cited by 64
Changes in lipid profile in response to three different protocols of whole-body cryostimulation treatments
Lubkowska, A., Banfi, G., Dołęgowska, B., d’Eril, G. V. M., Łuczak, J., & Barassi, A. (2010) · Cryobiology · doi:10.1016/j.cryobiol.2010.03.010 · Cited by 64
“HDL, the beneficial form of blood cholesterol, protects the artery wall against atherosclerosis and cardiovascular disease [11,12].”
Background
The Effect of Polyphenols in Olive Oil on Heart Disease Risk Factors
Covas, M., & Salonen, J. T. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00015 · Cited by 64
Rationale of the diet-heart statement of the American Heart Association. Report of the Nutrition Committee.
Chait, A., Brunzell, J. D., Denke, M. A., Eisenberg, D., Ernst, N. D., Franklin, F. A., Ginsberg, H., Kotchen, T. A., Kuller, L. H., & Mullis, R. M. (1993) · Circulation · doi:10.1161/01.cir.88.6.3008 · Cited by 256
Age and secular trends in risk factors for cardiovascular disease in Busselton
Knuiman, M. W., Jamrozik, K. D., Welborn, T. A., Bulsara, M. K., Divitini, M., & Whittall, D. E. (1995) · Australian Journal of Public Health · doi:10.1111/j.1753-6405.1995.tb00389.x · Cited by 64
Do Total and High Density Lipoprotein Cholesterol and Triglycerides Act Independently in the Prediction of Ischemic Heart Disease?
YARNELL, J. W. G., Patterson, C. C., Sweetnam, P. M., Thomas, H. F., Bainton, D., Elwood, P. C., Bolton, C., & Miller, N. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0801.093505 · Cited by 64
“Preexisting IHD was adjusted for by including 3 factors in the logistic regression models: (1) angina (none, grade I, or grade II) from the chest pain questionnaire, (2) history of severe chest pain lasting half an hour or more (yes or no) from the chest pain questionnaire, and (3) evidence of ischemia (none, possible…”
Method
Chronic hepatitis B virus infection and dyslipidemia.
Su, T., Lee, Y., Cheng, T., Chien, H.-P., & Wang, J. (2004) · PubMed · Cited by 63
Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet
Song, G., Liu, J., Zhao, Z., Yu, Y., Tian, H., Yao, S., Li, G., & Qin, S. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-8 · Cited by 63
“Plasma concentrations of HDL-C have strong inverse correlations with risk of atherosclerotic cardiovascular disease, independently of LDL-C levels [10].”
Background
Both STAT3 activation and cholesterol efflux contribute to the anti-inflammatory effect of apoA-I/ABCA1 interaction in macrophages
Tang, C., Houston, B. A., Storey, C., & LeBoeuf, R. C. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m065797 · Cited by 63
HDL and the menopause
Khoudary, S. R. E. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000432 · Cited by 66
Hypercholesterolemia Induces Oxidant Stress That Accelerates the Ageing of Hematopoietic Stem Cells
Tie, G., Messina, K. E., Yan, J., Messina, J. A., & Messina, L. M. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000241 · Cited by 65
“Taken together, we provide evidence that hypercholesterolemia can cause oxidant stress that accelerates the ageing and impairs the reconstitution capacity of HSCs. ( J Am Heart Assoc.”
BackgroundResultInfluential
Association Between a Novel 11–Base Pair Deletion Mutation in the Promoter Region of the Scavenger Receptor Class B Type I Gene and Plasma HDL Cholesterol Levels in Taiwanese Chinese
Hsu, L., Ko, Y., Wu, S., Teng, M., Peng, T.-Y., Chen, C.-F., Chen, C.-F., & Lee, Y. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000082525.84814.a9 · Cited by 62
The replacement of arginine by cysteine at residue 151 in Apolipoprotein A-I produces a phenotype similar to that of Apolipoprotein A-I Milano
Bruckert, É., von Eckardstein, A., Funke, H., Beucler, I., Wiebusch, H., Turpin, G., & Assmann, G. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(96)05982-5 · Cited by 62
Assembly of high density lipoprotein by the ABCA1/apolipoprotein pathway
Yokoyama, S. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000169346.15450.90 · Cited by 61
Epidemiological aspects of high density lipoprotein cholesterol1Presented at the 68th meeting of the European Atherosclerosis Society, Brugge, 8–10 May, 1997.1
Backer, G. D., Bacquer, D. D., & Kornitzer, M. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00310-9 · Cited by 62
Effect of Overexpression of Human Apo A-I in C57BL/6 and C57BL/6 Apo E–Deficient Mice on 2 Lipoprotein-Associated Enzymes, Platelet-Activating Factor Acetylhydrolase and Paraoxonase
Geest, B. D., Stengel, D., Landeloos, M., Lox, M., Gat, L. L., Collen, D., Holvoet, P., & Ninio, E. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.10.e68 · Cited by 62
“Discussion The main findings of the present study are that (1) PAF-AH, arylesterase, and paraoxonase activities are significantly lower in apo E mice than in wild-type C57BL/6 mice, indicating an impaired anti-inflammatory and antioxidative potential of HDL in C57BL/6 apo E 2/2 mice; (2) overexpres sion of human apo A…”
Result
Very low levels of HDL cholesterol and atherosclerosis, a variable relationship – a review of LCAT deficiency
Couffinhal, T., Savel, Lafitte, Couffinhal, T., & Tabarin (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s29985 · Cited by 63
“Introduction Several studies have demonstrated an inverse correlation between plasma high-density lipoprotein (HDL) and the risk of coronary artery disease, and have concluded that HDL is a powerful predictor of the disease.(1,2) Mutations in lecithin-cholesterol acyltransferase (LCAT), apolipoprotein A-1 (ApoA-1), an…”
Background
Unusual high-density lipoprotein subclass distribution during late pregnancy
Silliman, K., Tall, A. R., Kretchmer, N., & Forte, T. M. (1993) · Metabolism · doi:10.1016/0026-0495(93)90156-i · Cited by 61
The evidence for exercise-induced inflammation in intermittent claudication: Should we encourage patients to stop walking?
Tisi, P. V., & Shearman, C. (1998) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/s1078-5884(98)80066-x · Cited by 61
Effects of Ocular Carteolol and Timolol on Plasma High-density Lipoprotein Cholesterol Level
Freedman, S. F., Freedman, N. J., Shields, M. B., Lobaugh, B., Samsa, G. P., Keates, E. U., & Ollie, A. R. (1993) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)73203-9 · Cited by 61
Effect of testosterone enanthate on serum lipoproteins in man
Anderson, R. A., Wallace, E. M., & Wu, F. C. W. (1995) · Contraception · doi:10.1016/s0010-7824(95)00136-0 · Cited by 61
Alteration of lipid profiles in plasma of transgenic mice expressing human lipoprotein lipase
Min, L. I. U., Jirik, F. R., LeBoeuf, R. C., Henderson, H., Castellani, L. W., Lusis, A. J., Ma, Y., Forsythe, I. J., Zhang, H., & Kirk, E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78140-x · Cited by 61
The protein cargo of HDL: Implications for vascular wall biology and therapeutics
Heinecke, J. W. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.005 · Cited by 59
“Clinical and epidemiological studies consistently demonstrate a strong, inverse association of HDL cholesterol (HDL-C) level with CAD risk (1,2).”
Background
HDL and its sphingosine-1-phosphate content in cardioprotection
Keul, P., Sattler, K., & Levkau, B. (2007) · Heart Failure Reviews · doi:10.1007/s10741-007-9038-x · Cited by 59
“The most potent anti-atherogenic factor in humans is HDL which independently predicts the epidemiologic risk of cardiovascular events [1, 2].”
Background
Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects
Ronsein, G. E., Hutchins, P. M., Isquith, D. A., Vaisar, T., Zhao, X.-Q., & Heinecke, J. W. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306268 · Cited by 60
“404 The risk of cardiovascular disease (CVD) associates inversely and robustly with levels of high-density lipoprotein cholesterol (HDL-C).(1) However, recent trials of drugs that elevate HDL-C levels, such as niacin and cholesteryl ester transfer protein inhibitors, failed to reduce cardiac events in statin-treated s…”
Background
Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease
Vaziri, N. D. (2017) · Frontiers in bioscience · doi:10.2741/4585 · Cited by 62
“There are numerous studies which demonstrate that in the general population increasing serum concentrations of HDL cholesterol are associated with reduced risk of CV disease and mortality and improved outcomes (70, 71).”
Background
High density lipoprotein mediates selective reduction in cholesteryl esters from macrophage foam cells
Miyazaki, A., Rahim, A. T. M. A., Ohta, T., Morino, Y., & Horiuchi, S. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90219-l · Cited by 60
Compound Heterozygosity for a Structural Apolipoprotein A-I Variant, Apo A-I(L141R) Pisa , and an Apolipoprotein A-I Null Allele in Patients With Absence of HDL Cholesterol, Corneal Opacifications, and Coronary Heart Disease
Miccoli, R., Bertolotto, A., Navalesi, R., Odoguardi, L., Boni, A., Weßling, J., Funke, H., Wiebusch, H., von Eckardstein, A., & Assmann, G. (1996) · Circulation · doi:10.1161/01.cir.94.7.1622 · Cited by 59
High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants
van Acker, B. A. C., Botma, G.-J., Zwinderman, A. H., Kuivenhoven, J. A., Dallinga‐Thie, G. M., Sijbrands, E. J. G., Boer, J. M. A., Seidell, J. C., Jukema, J. W., Kastelein, J. J. P., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.019 · Cited by 59
“Epidemiological studies have demonstrated an inverse elationship between the concentration of high-density ipoprotein (HDL) cholesterol in plasma (HDL-c) and the isk of coronary artery disease (CAD) [1].”
Background
ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore
Tan, J. H.-H., Low, P., Tan, Y.-S., Tong, M.-C., Saha, N., Yang, H., & Heng, C. (2003) · Human Genetics · doi:10.1007/s00439-003-0943-3 · Cited by 59
“Among the lipoproteins, high-density lipoprotein-cholesterol (HDL-C) levels are strongly inversely correlated with CAD ( Gordon and Rifkind 1989 ).”
Background
Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review
Τζιόμαλος, Κ., & Athyros, V. G. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.129 · Cited by 58
A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects
Shao, B., de Boer, I. H., Tang, C., Mayer, P. S., Zelnick, L. R., Afkarian, M., Heinecke, J. W., & Himmelfarb, J. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00060 · Cited by 57
New insights into the biogenesis of human high-density lipoproteins
Krimbou, L., Marcil, M., & Genest, J. J. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000226117.43178.7c · Cited by 57
High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension
Schillaci, G., Vaudo, G., Reboldi, G., Verdecchia, P., Lupattelli, G., Pasqualini, L., Porcellati, C., & Mannarino, E. (2001) · Journal of Hypertension · doi:10.1097/00004872-200112000-00021 · Cited by 58
Validation of a questionnaire to assess niacin-induced cutaneous flushing
Norquist, J. M., Watson, D. J., Yu, Q., Paolini, J. F., McQuarrie, K., & Santanello, N. C. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x199637 · Cited by 58
“The recruiting site was asked to recruit patients with varying experiences related to these medications: (1) long-term users, (2) patients who had been taking the medication less than 2 weeks at the time of the pretest, and (3) patients who had previously taken one of these medications but discontinued its use.”
Background
Clinical significance of High-Density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate–Binding cassette protein A1 transporter
Brewer, H. B., & Santamarina-Fojo, S. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00769-0 · Cited by 57
HDL3Stimulates Multiple Signaling Pathways in Human Skin Fibroblasts
Walter, M., Reinecke, H., Nofer, J., Seedorf, U., & Assmann, G. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.11.1975 · Cited by 58
Aging and HDL Metabolism in Elderly People More Than 100 Years Old
Arai, Y., & Hirose, N. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.246 · Cited by 57
Effects of Increasing High-Density Lipoprotein Cholesterol and Decreasing Low-Density Lipoprotein Cholesterol on the Incidence of First Acute Coronary Events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study)
Cui, Y. A., Watson, D. J., Girman, C. J., Shapiro, D. R., Gotto, A. M., Hiserote, P., & Clearfield, M. B. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.020 · Cited by 57
High‐density lipoproteins augment hypoxia‐induced angiogenesis via regulation of post‐translational modulation of hypoxia‐inducible factor 1α
Tan, J. T. M., Prosser, H. C. G., Vanags, L. Z., Monger, S., Ng, M., & Bursill, C. A. (2013) · The FASEB Journal · doi:10.1096/fj.13-233874 · Cited by 59
Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations
Lu, Y., Dollé, M. E. T., Imholz, S., Slot, R. V. ‘., Verschuren, W. M. M., Wijmenga, C., Feskens, E. J. M., & Boer, J. M. A. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800232-jlr200 · Cited by 56
Differential response to low-fat diet between low and normal HDL-cholesterol subjects
Asztalos, B. F., LeFevre, M. L., Wong, L., Foster, T. A., Tulley, R. T., WINDHAUSER, M. M., Zhang, W., & Roheim, P. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34470-9 · Cited by 57
Astaxanthin Enhances ATP-Binding Cassette Transporter A1/G1 Expressions and Cholesterol Efflux from Macrophages
Iizuka, M., Ayaori, M., Uto‐Kondo, H., Yakushiji, E., Takiguchi, S., NAKAYA, K., Hisada, T., Sasaki, M., Komatsu, T., Yogo, M., et al. (2012) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.58.96 · Cited by 57
The role of cholesterol efflux in mechanisms of endothelial protection by HDL
Prosser, H. C. G., Ng, M. K. C., & Bursill, C. A. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352c4dd · Cited by 59
“It is well established that HDL are cardioprotective [1,2].”
Background
Relationship between serum HDL-C levels and common genetic variants of the endothelial lipase gene in Japanese school-aged children
Yamakawa‐Kobayashi, K., Yanagi, H., Endo, K., Arinami, T., & Hamaguchi, H. (2003) · Human Genetics · doi:10.1007/s00439-003-0985-6 · Cited by 57
“Many epidemiological and clinical studies have shown that low serum high-density lipoprotein cholesterol (HDL-C) and apolipoprotein AI (apoAI) levels are strongly associated with an increased risk of coronary heart disease (CHD) (Gordon et al. 1977; Castelli et al. 1986; Gordon and Rifkind 1989; Tall et al. 2002).”
Apolipoprotein A-I but not high-density lipoproteins are internalised by RAW macrophages: roles of ATP-binding cassette transporter A1 and scavenger receptor BI
Lorenzi, I., von Eckardstein, A., Cavelier, C., Radosavljevic, S., & Rohrer, L. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0267-1 · Cited by 57
In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia.
Schaefer, J. R., Rader, D. J., Ikewaki, K., Fairwell, T., Zech, L. A., Kindt, M. R., Davignon, J., Gregg, R. E., & Brewer, H. B. (1992) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.12.7.843 · Cited by 57
“Decreased plasma concentrations of HDL cholesterol and apo A-I are risk factors for coronary heart disease (CHD), independent of LDL cholesterol level.(33) Even within the heterozygous FH population, HDL cholesterol level is inversely related to the incidence and severity of CHD.”
Background
Suppression of Endogenous Testosterone in Young Men Increases Serum Levels of High Density Lipoprotein Subclass Lipoprotein A-I and Lipoprotein(a)
von Eckardstein, A., Kliesch, S., Nieschlag, E., Chirazi, A., Assmann, G., & Behre, H. M. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.10.4267 · Cited by 61
A fresh look at the atherogenic remnant hypothesis
Slyper, A. H. (1992) · The Lancet · doi:10.1016/0140-6736(92)92368-p · Cited by 57
Eyeballing cholesterol efflux and macrophage function in disease pathogenesis
Sène, A., & Apte, R. S. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.10.007 · Cited by 56
“On the other hand, deficiency in CETP increases plasma HDL-cholesterol, a significant observation because plasma HDL-cholesterol level is inversely related to atherosclerosis [41, 42], owing to its ability to promote reverse cholesterol transport, endothelial cell repair and its anti-inflammatory and antithrombotic pr…”
Background
Abnormal HDL Apolipoprotein A-I and A-II Kinetics in Hemodialysis Patients
Okubo, K., Ikewaki, K., Sakai, S., Tada, N., Kawaguchi, Y., & Mochizuki, S. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000117286.85443.7d · Cited by 56
Postprandial decrease in HDL cholesterol and HDL apo A-I in normal subjects in relation to triglyceride metabolism
de Bruin, T. W. A., Brouwer, C. B., Gimpel, J. A., & Erkelens, D. W. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.3.e492 · Cited by 56
Cholesteryl Ester Transfer Protein Activity Enhances Plasma Cholesteryl Ester Formation
Oliveira, H. C. F., Ma, L., Milne, R. W., Marcovina, S. M., Inazu, A., Mabuchi, H., & Tall, A. R. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.6.1045 · Cited by 56
Regulation of SR-BI protein levels by phosphorylation of its associated protein, PDZK1
Nakamura, T., Shibata, N., Nishimoto-Shibata, T., Feng, D., Ikemoto, M., Motojima, K., Iso-O, N., Tsukamoto, K., Tsujimoto, M., & Arai, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506679102 · Cited by 55
RISK and SAFE Signaling Pathway Involvement in Apolipoprotein A-I-Induced Cardioprotection
Kalakech, H., Hibert, P., Mirebeau‐Prunier, D., Tamareille, S., Letournel, F., Macchi, L., Pinet, F., Furber, A., & Prunier, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107950 · Cited by 57
“epidemiological studies [40].”
High-Density Lipoprotein Carries Markers That Track With Recovery From Stroke
Plubell, D. L., Fenton, A. M., Rosário, S., Bergstrom, P., Wilmarth, P. A., Clark, W. M., Zakai, N. A., Quinn, J. F., Minnier, J., Alkayed, N. J., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.316526 · Cited by 56
Group V and X secretory phospholipase A2s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions
Ishimoto, Y., Yamada, K., Yamamoto, S., Ono, T., Notoya, M., & Hanasaki, K. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(03)00120-4 · Cited by 55
“Introduction coronary artery disease [1].”
Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency.
Ohta, T., Nakamura, R., Takata, K., Saito, Y., Yamashita, S., Horiuchi, S., & Matsuda, I. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40055-0 · Cited by 55
Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia
Rader, D. J., Schaefer, J. R., Lohse, P., Ikewaki, K., Fairwell, T., Harris, W. A., Zech, L. A., Dujovne, C. A., & Brewer, H. B. (1993) · Metabolism · doi:10.1016/0026-0495(93)90194-s · Cited by 55
Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis
Saku, K., Zhang, B., Ohta, T., & Arakawa, K. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00560-9 · Cited by 55
“An inverse relationship between plasma levels of high density lipoprotein cholesterol (HDL-C) and the risk for coronary artery disease (CAD) has been well established (1,2).”
Background
The Complete Health Improvement Program (CHIP)
Morton, D. P., Rankin, P. M., Kent, L. M., & Dysinger, W. S. (2014) · American Journal of Lifestyle Medicine · doi:10.1177/1559827614531391 · Cited by 58
“Epidemiological studies have indicated that low HDL levels are an important risk factor for cardiovascular disease.(48) As such, they have become 1 of the 5 criteria for the diagnosis of the metabolic syndrome (MetS).”
SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL
Yvan‐Charvet, L., Pagler, T. A., Wang, N., Senokuchi, T., Brundert, M., Li, H., Rinninger, F., & Tall, A. R. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700200-jlr200 · Cited by 54
“HDL cholesterol levels are inversely correlated with the incidence of coronary artery disease (1).”
Background
Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice
Schlitt, A., Liu, J., Yan, D., Mondragon-Escorpizo, M. O., Norin, A. J., & Jiang, X. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2004.12.011 · Cited by 54
Restoration of High-Density Lipoprotein Levels by Cholesteryl Ester Transfer Protein Expression in Scavenger Receptor Class B Type I (SR-BI) Knockout Mice Does Not Normalize Pathologies Associated With SR-BI Deficiency
Hildebrand, R. B., Lammers, B., Meurs, I., Korporaal, S. J. A., de Haan, W., Zhao, Y., Kruijt, J. K., Praticò, D., Schimmel, A. W. M., Holleboom, A. G., et al. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.205153 · Cited by 54
“SR-BI, however, has also been implicated in several other processes that might have influenced atherosclerotic lesion development in SR-BI and SR-BI/CETP mice: (1) locally in the arterial wall, macrophage SR-BI induces early lesion development by facilitating the uptake of both modified and native lipoproteins, and it…”
Background
Alterations in plasma lipids, lipoproteins and high density lipoprotein subfractions in peripheral arterial disease
Mowat, B., SKINNER, E. R., Wilson, H. M., Leng, G. C., Fowkes, F. G. R., & Horrobin, D. F. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)06097-8 · Cited by 54
“Indeed, the ratio of LDL-cholesterol to HDL-cholesterol has been shown to be one of the strongest predictors of coronary heart disease in asymptomatic subjects and is more than ten times more powerful than the measurement of total plasma-cholesterol [1,2].”
Background
Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol
Kark, J. D., Sinnreich, R., Leitersdorf, E., Friedlander, Y., Shpitzen, S., & Luc, G. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00408-6 · Cited by 54
“heart disease (CHD) evident elsewhere [3,4] is apparent”
Background
Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-I (ApoA-I) variants with murine adipocytes and macrophages. Evidence for reduced cholesterol efflux promotion by apoA-I(Pro165–>Arg).
von Eckardstein, A., Castro, G., Wybrańska, I., Théret, N., Duchateau, P. N., Duverger, N., Fruchart, J., Ailhaud, G. P., & Assmann, G. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53819-9 · Cited by 54
High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus
He, Y., Kothari, V. M., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310222 · Cited by 56
Decreased levels of serum nitric oxide in different forms of dementia
Corzo, L., Zas, R., Rodríguez, S., Fernández‐Novoa, L., & Cacabelos, R. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.05.008 · Cited by 53
Retrovirus-mediated Expression of Apolipoprotein A-I in the Macrophage Protects against Atherosclerosis in Vivo
Ishiguro, H., Yoshida, H., Major, A. S., Zhu, T., Babaev, V. R., Linton, M. F., & Fazio, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106027200 · Cited by 53
Apolipoprotein A-IMilano and 1-Palmitoyl-2-oleoyl Phosphatidylcholine Complex (ETC-216) Protects the in Vivo Rabbit Heart from Regional Ischemia-Reperfusion Injury
Marchesi, M., Booth, E. A., Davis, T., Bisgaier, C. L., & Lucchesi, B. R. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.070789 · Cited by 53
“High-density lipoproteins (HDLs) retard formation of lipid-rich arterial lesions and may prevent plaque rupture and coronary events (Gordon and Rifkind, 1989; Badimon et al., 1992).”
Background
Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE
Krimbou, L., Tremblay, M., Davignon, J., & Cohn, J. S. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37273-4 · Cited by 53
High Density Lipoprotein Stimulated Migration of Macrophages Depends on the Scavenger Receptor Class B, Type I, PDZK1 and Akt1 and Is Blocked by Sphingosine 1 Phosphate Receptor Antagonists
Al‐Jarallah, A., Chen, X., González, L., & Trigatti, B. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106487 · Cited by 55
“An inverse relationship between circulating levels of HDL and coronary heart disease has been reported in numerous clinical and epidemiological studies [20–22].”
Background
Cholesterol and Plant Sterol Efflux from Cultured Intestinal Epithelial Cells Is Mediated by ATP-Binding Cassette Transporters
Tachibana, S., Hirano, M., Hirata, T., Matsuo, M., Ikeda, I., Ueda, K., & Sato, R. (2007) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.70109 · Cited by 52
Common Variation in the CETP Gene and the Implications for Cardiovascular Disease and its Treatment: An Updated Analysis
Dullaart, R. P. F., & Sluiter, W. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.6.747 · Cited by 52
Lipid packing determines protein–membrane interactions: Challenges for apolipoprotein A-I and high density lipoproteins
Sánchez, S. A., Tricerri, M. A., Ossato, G., & Gratton, E. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.03.019 · Cited by 52
Relative effects of weight loss and dietary fat modification on serum lipid levels in the dietary treatment of obesity.
Leenen, R. C. A., Kooy, K. V. D., Meyboom, S., Seidell, J. C., Deurenberg, P., & Weststrate, J. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35359-1 · Cited by 52
Recombinant apolipoproteins for the treatment of vascular diseases
Sirtori, C. R., Calabresi, L., & Franceschini, G. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00247-0 · Cited by 51
“[9] Gordon DJ, Rifkind BM.”
Background
Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study
Frénais, R., Ouguerram, K., Maugeais, C., Marchini, J. S., Benlian, P., Bard, J., Magot, T., & Krempf, M. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33394-0 · Cited by 52
Human Apolipoproteins A-I and A-II in Cell Cholesterol Efflux
Chiesa, G., Parolini, C., Canavesi, M., Colombo, N., Sirtori, C. R., Fumagalli, R., Franceschini, G., & Bernini, F. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.9.1417 · Cited by 52
Apolipoprotein A-I Zavalla (Leu 159 →Pro)
Miller, M. J., Aiello, D. P., Pritchard, H., Friel, G., & Zeller, K. I. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.8.1242 · Cited by 51
β-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-α-lipoproteinaemia
Pocovı́, M., Cenarro, A., Civeira, F., Torralba, M. A., Pérez‐Calvo, J. I., Mozas, P., Giraldo, P., Giralt, M., Myers, R. H., Cupples, L. A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09490-7 · Cited by 52
Biochemical characterization of the three major subclasses of lipoprotein A-I preparatively isolated from human plasma
Duverger, N., Rader, D. J., Duchateau, P. N., Fruchart, J., Castro, G. R., & Brewer, H. B. (1993) · Biochemistry · doi:10.1021/bi00097a014 · Cited by 52
Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits
Iwata, A., Miura, S., Zhang, B., Imaizumi, S., Uehara, Y., Shiomi, M., & Saku, K. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.05.029 · Cited by 51
Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes
Li, X., Millar, J. S., Brownell, N. K., Briand, F., & Rader, D. J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.023 · Cited by 52
Extra Virgin Olive Oil Polyphenols Promote Cholesterol Efflux and Improve HDL Functionality
Berrougui, H., Ikhlef, S., & Khalil, A. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/208062 · Cited by 51

Authors: Desforges, J. F., Gordon, D. J., & Rifkind, B. M.
Affiliations: National Heart, Lung, and Blood Institute (US)
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1989-11-09
Volume: 321
Issue: 19
Pages: 1311-1316
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm198911093211907
OpenAlex: W2339616051
Cited by: 1,547
References: 50
Citations by year: 2026: 9 · 2025: 6 · 2024: 15 · 2023: 19 · 2022: 13 · 2021: 22 · 2020: 22 · 2019: 30 · 2018: 21 · 2017: 24 · 2016: 36 · 2015: 47 · 2014: 42 · 2013: 42 · 2012: 38
FWCI: 9.17
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: high-density lipoprotein, HDL cholesterol, coronary artery disease, atherogenesis, cardioprotection, HDL metabolism, Helsinki Heart Study
MeSH terms: Coronary Disease, Humans, Lipoproteins, HDL, Cholesterol, HDL

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

High-Density Lipoprotein — The Clinical Implications of Recent Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks